The stock closed at ₹911.20, down 3.85% from the previous close of ₹947.70, with intraday prices ranging between ₹911.20 and ₹948.85. Over the past week, Alembic Pharmaceuticals recorded a return of -0.59%, contrasting with the Sensex's 0.96% gain. Monthly and year-to-date returns also show a negative trend for the stock at -2.81% and -13.97% respectively, while the Sensex posted positive returns of 0.86% and 8.36% over the same periods. Longer-term returns present a mixed picture, with a 3-year return of 45.71% surpassing the Sensex's 37.31%, but a 5-year return of -6.05% lagging behind the Sensex's 91.65%.
Transformation in full progress! This Micro Cap from Auto Ancillary just achieved sustainable profitability after tough times. Be early to witness this powerful comeback story!
- Sustainable profitability reached
- Post-turnaround strength
- Comeback story unfolding
Examining technical indicators, the Moving Average Convergence Divergence (MACD) presents a bearish signal on the weekly chart and a mildly bearish stance on the monthly chart. The Relative Strength Index (RSI) remains neutral with no clear signal on both weekly and monthly timeframes. Bollinger Bands suggest a mildly bearish outlook across weekly and monthly periods, indicating potential price consolidation or downward pressure. Daily moving averages, however, maintain a mildly bullish posture, suggesting short-term support for the stock price.
Additional momentum indicators such as the Know Sure Thing (KST) oscillator and Dow Theory analysis reflect a mildly bearish trend on monthly charts and a bearish trend on weekly charts. The On-Balance Volume (OBV) indicator shows a divergence with a mildly bearish weekly signal but a bullish monthly signal, hinting at mixed volume dynamics influencing price movement.
Alembic Pharmaceuticals . or something better? Our SwitchER feature analyzes this small-cap Pharmaceuticals & Biotechnology stock and recommends superior alternatives based on fundamentals, momentum, and value!
- SwitchER analysis complete
- Superior alternatives found
- Multi-parameter evaluation
From a market capitalisation perspective, Alembic Pharmaceuticals holds a grade of 3, reflecting its standing within the Pharmaceuticals & Biotechnology sector. The Mojo Score currently stands at 64.0, with a recent adjustment in evaluation noted on 17 Nov 2025, shifting from a previous grade of Sell to Hold. This revision aligns with the technical parameter changes triggered on 19 Nov 2025, indicating a recalibration of the stock’s momentum and risk profile.
Comparing Alembic Pharmaceuticals’ price range over the past 52 weeks, the stock has traded between ₹725.60 and ₹1,122.40, illustrating significant volatility within the sector. The current price level near ₹911.20 situates the stock below its 52-week high, reflecting the recent technical momentum shifts and broader market conditions.
Investors analysing Alembic Pharmaceuticals should consider the mixed signals from technical indicators alongside the stock’s relative performance against the Sensex. The mildly bearish technical trend on weekly and monthly charts contrasts with short-term mildly bullish moving averages, suggesting a period of consolidation or cautious trading ahead. Volume-based indicators and momentum oscillators further highlight the complexity of the current price action, underscoring the importance of a comprehensive approach to evaluation.
Overall, Alembic Pharmaceuticals presents a nuanced technical profile with recent adjustments in its evaluation parameters. Market participants may find value in monitoring these technical signals in conjunction with sector trends and broader market movements to better understand potential price trajectories.
Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →
